https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-01 / BioDrugs 2013 Feb;27(1):35-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-01 / BioDrugs 2013 Feb;27(1):35-532013-02-01 00:00:002021-11-15 16:56:59Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-23 / J. Virol. 2013 Apr;87(7):3792-800
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-23 / J. Virol. 2013 Apr;87(7):3792-8002013-01-23 00:00:002013-01-23 00:00:00Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-10 / Biofactors 2013 Jan-Feb;39(1):56-68
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-10 / Biofactors 2013 Jan-Feb;39(1):56-682013-01-10 00:00:002013-01-10 00:00:00Curcumin in various cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-10 / Biofactors 2013 Jan-Feb;39(1):27-36
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-10 / Biofactors 2013 Jan-Feb;39(1):27-362013-01-10 00:00:002013-01-10 00:00:00Molecular mechanisms of curcumin action: signal transduction
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-10 / Transl Res 2013 Apr;161(4):355-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-10 / Transl Res 2013 Apr;161(4):355-642013-01-10 00:00:002019-02-15 09:22:40Oncolytic virus therapy for cancer: the first wave of translational clinical trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-01 / Oncoimmunology 2013 Jan;2(1):e22664
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-01 / Oncoimmunology 2013 Jan;2(1):e226642013-01-01 00:00:002020-02-05 10:32:57Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-01 / Acupunct Electrother Res 2013;38(3-4):161-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-01 / Acupunct Electrother Res 2013;38(3-4):161-972013-01-01 00:00:002013-01-01 00:00:00Oncothermia: a new paradigm and promising method in cancer therapies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-28 / J Med Case Rep 2012 Dec;6:427
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-28 / J Med Case Rep 2012 Dec;6:4272012-12-28 00:00:002012-12-28 00:00:00A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-27 / BMC Cancer 2012 Dec;12:623
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-27 / BMC Cancer 2012 Dec;12:6232012-12-27 00:00:002019-02-15 08:46:31α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-17 / Int J Hyperthermia 2013;29(1):8-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-17 / Int J Hyperthermia 2013;29(1):8-162012-12-17 00:00:002012-12-17 00:00:00Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
